Cathie Wood’s ARK ETF published their daily trades for Thursday, May 8th, 2025, showcasing a series of strategic transactions across their funds. Leading the day’s activity was a significant purchase of Shopify Inc (NYSE:NASDAQ:SHOP) shares, with ARK investing in a total of 228,824 shares across three ETFs, amounting to a substantial $21,623,868. This move underscores ARK’s growing interest in the e-commerce platform, following a pattern of accumulation in recent days.
Another notable buy was GitLab Inc (NASDAQ:GTLB), with ARK adding 31,560 shares through its ARKK ETF, valued at $1,485,844. This follows a consistent buying trend in GitLab over the past week, suggesting ARK’s conviction in the company’s growth prospects.
ARK also increased its stake in Veracyte Inc (NASDAQ:VCYT), buying 88,385 shares across two ETFs, translating to a $2,725,793 investment. This purchase comes after a sell-off of Veracyte shares last Friday, indicating a possible strategic readjustment in ARK’s position on the genomic diagnostics company.
On the sell side, ARK offloaded a significant portion of Palantir Technologies Inc (NYSE:NASDAQ:PLTR) stock, divesting 135,572 shares through its ARKK, ARKW, and ARKF ETFs, with a total dollar value of $14,977,994. This sale continues a trend of reducing exposure to Palantir seen in previous sessions.
Additionally, ARK sold 256,593 shares of Block Inc (NYSE:XYZ), a financial services and digital payments company, across three ETFs, cashing out $12,303,634. This move marks a notable sell, given the sizeable dollar value and the distribution of the sale across multiple funds.
Other sales included Adaptive Biotechnologies Corp (NASDAQ:ADPT), Arcturus Therapeutics Holdings Inc (NASDAQ:ARCT), and CareDx Inc (NASDAQ:CDNA), with ARK selling $459,485, $271,253, and $486,671 worth of shares, respectively, all through the ARKG ETF. These transactions, though smaller in comparison, still reflect ARK’s active portfolio management and ongoing assessment of the biotech sector.
Lastly, ARK’s acquisition of 6,433 shares of CRISPR Therapeutics AG (NASDAQ:CRSP) for $220,330 continues a pattern of investment in the gene-editing company, following a more substantial buy earlier in the week.
Investors following Cathie Wood’s ARK ETF trades can observe a dynamic approach to portfolio management, with Wood and her team making calculated adjustments based on market conditions and the long-term potential of their holdings.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.